The latest shared research on CancerPartnersUK
Scrip Roundtable Cancer Vaccines: Future Role – How Will Treatment Strategies Change with the Arrival of Cancer Vaccines?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip’s editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip Intelligence Future role: how will treatment strategies change with the arrival of cancer vaccines? Cancer vaccines will take their place in the treatment armoury but personalisation ...
Scrip Roundtable Cancer Vaccines: Pharma’s Role – What Part Should Industry Play in Cancer Vaccine Development?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip’s editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip Intelligence Pharma's role: what part should industry play in cancer vaccine development? Pharma's drug discovery model has left it on the ...
Scrip Roundtable Cancer Vaccines: Show Me the Money – Will Cancer Vaccines be Rainmakers?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip’s editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip Intelligence Show me the money: will cancer vaccines be rainmakers? Good efficacy and good biomarkers will be crucial for proving cost-effectiveness ...
Scrip Roundtable Cancer Vaccines: Challenges – What’s Holding Back Development?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip’s editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip ...
Scrip Roundtable Cancer Vaccines: A New Weapon in the War on Cancer?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip's editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip Intelligence Meet the roundtable panelists ...
